



Arseus has assured credit facilities after IPO

EUR 200 million revolving credit facility with five renowned credit institutions

Nazareth, Belgium - 6 September 2007 (17:45 h CET) — Arseus has closed a EUR 200 million revolving credit facility agreement in anticipation of its Initial Public Offering (IPO).

Major step towards autonomy of Arseus

The agreement will enter into force upon the realization of the IPO. Its tenor is five years with the possibility of extending it to seven years.

After the IPO is completed, it is the intention to appropriate a part of this credit facility to replace the current financial debts of Arseus to Omega Pharma. However, a significant amount will remain available to Arseus for the implementation of its buy-and-build strategy.

The agreement has been closed in a 'club deal' structure, involving ING (facilitator), Fortis, KBC, Commerzbank and Dexia. This agreement and the competitive interest rates that have been granted, clearly express the confidence that each of the participating credit institutions has in Arseus.

Preparations on track for IPO in 2007

Considering the successful half-year results of Arseus (cf. press release dd. 29 August 2007), Omega Pharma expects to realize the Arseus IPO as scheduled in 2007. To this end, the required procedures have already been initiated with the competent authorities.

The IPO of Arseus will comprise both a capital increase by Arseus and a placement by Omega Pharma of a part of the existing Arseus shares. Omega Pharma plans to provide its existing shareholders with a priority subscription right in the Arseus IPO. Omega Pharma's reference shareholder Couckinvest NV intends to participate for its share in such priority tranche. Final Offering structure details will be described in a prospectus subject to the approval of the Belgian market authority.

Arseus, profile

Arseus generated a turnover of € 277 million in 2006, with 1,230 staff members. Arseus supplies health care professionals, on a European level, with products and services that enable them to provide high-quality services in an efficient manner. Arseus services pharmacists, general practitioners, specialist physicians, dentists, eye care professionals, nursing staff as well as hospitals and homes for the elderly. Ageing populations and the growing consumer awareness for health, well-being and aesthetics lead to a strong growth market for Arseus.

For more information, please contact:

Chris.Vanraemdonck@omega-pharma.be

Tel. 0032/9/381.03.31 - Mobile 0032/499/58.55.31 - www.omega-pharma.be